Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.750
+0.130 (4.96%)
At close: Sep 30, 2026, 4:00 PM EDT
2.750
0.00 (0.00%)
Pre-market: Oct 1, 2026, 4:03 AM EDT
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $81.00K in the quarter ending June 30, 2026, a decrease of -72.07%. This brings the company's revenue in the last twelve months to $409.00K, down -66.88% year-over-year. In the year 2025, Perspective Therapeutics had annual revenue of $884.00K, down -39.20%.
Revenue (ttm)
$409.00K
Revenue Growth
-66.88%
P/S Ratio
767.52
Revenue / Employee
$2,464
Employees
166
Market Cap
313.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 884.00K | -570.00K | -39.20% |
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Dec 31, 2022 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 833.19M |
| Viemed Healthcare | 301.61M |
| Treace Medical Concepts | 205.31M |
| InfuSystem Holdings | 143.34M |
| Standard BioTools | 84.60M |
| AVITA Medical | 75.63M |
| Shoulder Innovations | 60.06M |
| Mobia Medical | 45.28M |
CATX News
- 12 days ago - Perspective Therapeutics initiated with an Outperform at William Blair - TheFly
- 14 days ago - Perspective Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 16 days ago - Perspective Therapeutics announces trial collaboration agreement with Merck - TheFly
- 16 days ago - Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors - GlobeNewsWire
- 19 days ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - GlobeNewsWire
- 6 weeks ago - BMO Capital starts Perspective at Outperform, cites pipeline opportunities - TheFly
- 6 weeks ago - Perspective Therapeutics initiated with an Outperform at BMO Capital - TheFly
- 6 weeks ago - Perspective Therapeutics price target lowered to $5 from $6 at BofA - TheFly